QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SVRA

QT77Savara Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
5.50
+0.12+2.23%
OverviewShort InterestFilings
SVRAQT77Savara Inc.·NASDAQ
OverviewShort InterestFilings
5.50+2.23%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand204.93M
Perf Week4.36%
Market Cap1.10BForward P/E-EPS next Y-0.30Insider Trans0.35%Shs Float-Perf Month16.53%
Enterprise Value1.09BPEG0.79EPS next Q-0.14Inst Own-Short Float-Perf Quarter6.59%
Income-104738190.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-14.46%
Sales-P/B7.74EPS next Y44.73%ROA-58.42%Short Interest-Perf YTD-8.79%
Book/sh0.86P/C-EPS next 5Y-ROE-87.19%52W High7.01 -21.54%Perf Year169.61%
Cash/sh0.99P/FCF-EPS past 3/5Y-ROIC-65.06%52W Low1.98 177.78%Perf 3Y-
Dividend Est.-EV/EBITDA-8.46Sales past 3/5Y-Gross Margin0.00%Volatility3.04% 3.55%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-16.67%Oper. Margin0.00%ATR (14)0.27Perf 10Y-
Dividend Ex-Date-Quick Ratio13.47Sales Y/Y TTM-Profit Margin0.00%RSI (14)60.39Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.47EPS Q/Q-25.00%SMA205.89%Beta1.41Target Price10.00
Payout0.00%Debt/Eq0.17Sales Q/Q-SMA504.62%Rel Volume3.31Prev Close5.38
Employees59LT Debt/Eq0.15EarningsAug 12SMA2008.24%Avg Volume1.44MPrice5.50
IPO DateApr 28, 2017Option/ShortYes / YesEPS/Sales Surpr.-7.14% -Net Debt/EBITDA0.07Volume4,761,530Change2.23%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-16-26ReiteratedWilliam Blair$10
Dec-23-25ReiteratedOppenheimerOutperform$11 → $10
Dec-23-25ReiteratedUBS$10
Oct-23-25ReiteratedJMP SecuritiesMarket Outperform$9.00 → $11
Sep-09-25ReiteratedGuggenheimBuy$10 → $11
Aug-15-25ReiteratedH.C. WainwrightBuy$10 → $5.00
Aug-15-25UpgradeHC Wainwright & Co.Neutral → Buy
May-29-25DowngradeHC Wainwright & Co.Buy → Neutral
Nov-13-24DowngradeEvercore ISI GroupOutperform → In Line
Aug-13-24ReiteratedJMP SecuritiesMarket Outperform$10 → $9.00
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A07844
Gross Profit0-78-44
Selling, General and Administrative Excl. Other422516
Research and Development817844
Other Operating Expense0-78-44
Operating Income-124-103-60
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-5-1-1
Net Income Before Taxes-119-96-55
Income Taxes000
Consolidated Net Income-119-96-55
Net Income From Continuing Operations-119-96-55
Net Income-119-96-55
EPS (Recurring)-0.53-0.48-0.33
EPS (Basic, Before Extraordinaries)-0.53-0.48-0.33
EPS (Diluted)-0.53-0.48-0.33
EBITDA-119-102-59
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding222198165
Market Capitalization1,339——
Operating Lease Expense
———
Insider Trading Volume
$5.83$5.18$4.54$3.90$3.25● Close Price0.00K30.30K60.61K90.92K121.22KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lowrance David LChief Financial OfficerMar 18 '26Option Exercise1.60733,4941,176,912552,550Mar 20 12:00 AM
McCracken Joseph SDirectorFeb 16 '26Option Exercise1.763,6146,360302,644Feb 17 12:00 AM
RAMSAY DAVID ADirectorDec 19 '25Sale6.0620,000121,2202,533,642Dec 19 12:00 AM
Elam Nevan CDirectorDec 02 '25Option Exercise1.4611,72017,11268,360Dec 04 12:00 AM
Hawkins Richard JDirectorNov 14 '25Option Exercise1.4611,72017,112121,326Nov 17 12:00 AM
Hawkins Richard JDirectorJun 20 '25Buy2.0448,22598,572115,466Jun 23 12:00 AM
McCracken Joseph SDirectorMay 29 '25Buy2.0810,00020,825260,837Jun 02 12:00 AM
RAMSAY DAVID ADirectorMar 31 '25Buy2.77150,000416,2502,513,642Apr 01 12:00 AM
Lowrance David LChief Financial OfficerDec 16 '24Sale3.3325,00083,278381,005Dec 16 12:00 AM
Hawkins Richard JDirectorDec 16 '24Sale3.328,00026,56967,241Dec 16 12:00 AM
Pauls MatthewCHIEF EXECUTIVE OFFICERDec 16 '24Sale3.3154,702180,8281,536,379Dec 16 12:00 AM
McCracken Joseph SDirectorNov 19 '24Buy2.9520,00059,072210,837Nov 20 12:00 AM
RAMSAY DAVID ADirectorNov 18 '24Buy2.88100,000287,6002,323,642Nov 18 12:00 AM
Pauls MatthewCHIEF EXECUTIVE OFFICERDec 28 '23Sale4.7184,000395,9001,302,674Dec 29 12:00 AM
Lowrance David LCHIEF FINANCIAL OFFICERDec 28 '23Sale4.7110,00047,131342,355Dec 29 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR